-1%
Ventoxen contains Venetoclax, a small molecule that selectively inhibits BCL-2, a protein that prevents cell death (apoptosis) and is commonly overexpressed in CLL cells. This overexpression supports cancer cell survival and contributes to drug resistance. Venetoclax binds to BCL-2, releasing pro-apoptotic proteins like BIM, which leads to mitochondrial disruption and activation of enzymes that cause cell death. Preclinical studies confirm its effectiveness in destroying BCL-2–dependent tumor cells.
Ventoxen, when used alongside Rituximab, is prescribed for adults with chronic lymphocytic leukemia (CLL) who have previously undergone at least one line of therapy.
As a standalone treatment, Ventoxen is indicated for:
Adults with CLL and a 17p deletion or TP53 mutation who are either not suitable candidates for or have not responded to B-cell receptor pathway inhibitors.
Adults without the 17p deletion or TP53 mutation who have not responded to both chemoimmunotherapy and a B-cell receptor pathway inhibitor.